Get the Stockscreener App
27.36
0.58%
-0.15
After Hours:
27.44
0.08
+0.29%
Beam Therapeutics Inc stock is traded at $27.36, with a volume of 1.56M.
It is down -0.58% in the last 24 hours and up +25.06% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
See More
Previous Close:
$27.51
Open:
$27.495
24h Volume:
1.56M
Relative Volume:
0.66
Market Cap:
$2.78B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-15.12
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+0.96%
1M Performance:
+25.06%
6M Performance:
+56.82%
1Y Performance:
-2.53%
1-Day Range:
$26.83
$27.91
1-Week Range:
$25.86
$28.28
52-Week Range:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
27.36 | 2.79B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Cambridge biotech receives $255M in sale of spinout to BMS - The Business Journals
Evercore ISI Remains a Buy on Beam Therapeutics (BEAM) - The Globe and Mail
JonesTrading Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
ASH: Beam Can Rival Vertex In Sickle Cell But Bulsufan Deaths Cast A Shadow - Citeline News & Insights
Beam Therapeutics edges higher after new sickle cell therapy results - MSN
Beam Therapeutics stock rises on promising sickle cell therapy data By Investing.com - Investing.com Nigeria
Beam Therapeutics stock rises on promising sickle cell therapy data - Investing.com
(BEAM) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Reveals Positive Trial Results at Hemat - GuruFocus
Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON Sickle Cell Trial Results and Renewed Momentum - Yahoo Finance
Beam Therapeutics (BEAM) Is Up 6.9% After New BEACON Trial Data Spotlight Base-Editing Potential - Yahoo Finance
Beam reports positive data from sickle cell disease gene therapy trial By Investing.com - Investing.com South Africa
Beam reports positive data from sickle cell disease gene therapy trial - Investing.com
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - The Manila Times
Beam Therapeutics Reports Promising Updates on Risto-cel for Sickle Cell Disease at 67th ASH Annual Meeting - Quiver Quantitative
38,438 Shares in Beam Therapeutics Inc. $BEAM Purchased by Capital Fund Management S.A. - MarketBeat
Beam Therapeutics stock surges 64% since InvestingPro’s April undervalued call By Investing.com - Investing.com Australia
BEAM (Beam Therapeutics) Capex-to-Operating-Income : 0.00 (As of Sep. 2025) - GuruFocus
How Beam Therapeutics Inc. stock compares to industry benchmarksProfit Target & AI Powered Market Entry Strategies - Newser
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Beam Therapeutics (NASDAQ:BEAM) Stock Price Up 6.8%What's Next? - MarketBeat
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report? - Yahoo Finance
Published on: 2025-12-04 06:37:06 - Newser
Why analysts remain bullish on Beam Therapeutics Inc. stockJuly 2025 Trends & Community Verified Trade Signals - Newser
Beam Therapeutics Earnings Notes - Trefis
Beam Therapeutics (BEAM) Experiences Significant Stock Surge - GuruFocus
Will Beam Therapeutics Inc. stock split again soonSell Signal & Daily Volume Surge Trade Alerts - Newser
Will Beam Therapeutics Inc. stock pay special dividends2025 Stock Rankings & Precise Swing Trade Entry Alerts - Newser
Is Beam Therapeutics Inc. stock attractive for ETFsRate Cut & Safe Entry Point Identification - Newser
The Best CRISPR Companies for 2025 - The Motley Fool
Beam Therapeutics Advances BEAM-302 Study for AATD: Key Insights for Investors - MSN
Geode Capital Management LLC Grows Position in Beam Therapeutics Inc. $BEAM - MarketBeat
14,601 Shares in Beam Therapeutics Inc. $BEAM Bought by Entropy Technologies LP - MarketBeat
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? - sharewise.com
Beam Therapeutics (BEAM) Earnings Transcript - Nasdaq
How resilient is Beam Therapeutics Inc. stock in market downturnsOil Prices & Stepwise Swing Trade Plans - BỘ NỘI VỤ
Is Beam Therapeutics Inc. stock a defensive play in 20252025 Winners & Losers & Free Technical Pattern Based Buy Signals - BỘ NỘI VỤ
(BEAM) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
ETFs Investing in Beam Therapeutics Inc. Stocks - TradingView
Evercore ISI Group Initiates Coverage of Beam Therapeutics (BEAM) with Outperform Recommendation - MSN
Beam Therapeutics (BEAM) Receives New 'Outperform' Rating from E - GuruFocus
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
How Beam Therapeutics Inc. stock valuations compare to rivals - newser.com
Analyzing drawdowns of Beam Therapeutics Inc. with statistical toolsAnalyst Upgrade & Growth Oriented Trading Recommendations - newser.com
Is Beam Therapeutics Inc. stock supported by innovation pipeline2025 Key Lessons & Capital Efficiency Focused Strategies - newser.com
How Beam Therapeutics Inc. stock compares to market leaders2025 Biggest Moves & AI Powered Buy/Sell Recommendations - newser.com
Beam Therapeutics (BEAM) Strengthens Cash Position as Key Trials Move Forward - MSN
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '25 |
Sale |
24.53 |
467 |
11,456 |
44,045 |
| Bellon Christine | Chief Legal Officer |
Oct 01 '25 |
Sale |
24.53 |
373 |
9,150 |
116,921 |
| Evans John M. | CEO |
Oct 01 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Option Exercise |
0.67 |
25,000 |
16,750 |
1,011,667 |
| Evans John M. | CEO |
Oct 02 '25 |
Sale |
24.63 |
25,000 |
615,668 |
986,667 |
| Evans John M. | CEO |
Oct 01 '25 |
Sale |
24.51 |
25,000 |
612,655 |
986,667 |
1.13%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):